Focused On-demand Library for ATP-dependent RNA helicase SUPV3L1, mitochondrial

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8IYB8

UPID:

SUV3_HUMAN

Alternative names:

Suppressor of var1 3-like protein 1

Alternative UPACC:

Q8IYB8; A8K301; O43630

Background:

ATP-dependent RNA helicase SUPV3L1, mitochondrial, also known as Suppressor of var1 3-like protein 1, is a pivotal enzyme in mitochondrial RNA metabolism. It forms part of the mitochondrial degradosome complex, crucial for degrading double-stranded RNA in an ATP-dependent manner. This protein unwinds both DNA and RNA duplexes, playing a key role in mitochondrial RNA surveillance, stability of mRNAs, and chromatin maintenance. Its ability to prevent apoptosis underscores its importance in cellular survival.

Therapeutic significance:

Understanding the role of ATP-dependent RNA helicase SUPV3L1, mitochondrial could open doors to potential therapeutic strategies.